Cellectis SA, a prominent biopharmaceutical company headquartered in Paris, France, continues to make significant strides in the health care sector, particularly within the biotechnology industry. As of March 18, 2026, Cellectis’s stock closed at 2.97 EUR on the NYSE Euronext Paris, reflecting a dynamic market presence. The company’s market capitalization stands at approximately 298.76 million EUR, underscoring its substantial role in the biotech landscape.
Cellectis SA has carved a niche for itself by focusing on the development of innovative immunotherapies, specifically through the use of gene-edited CAR-T cells, known as UCART. This pioneering approach aims to revolutionize cancer treatment by engineering T-cells to target and destroy cancer cells more effectively. The company’s mission is to establish a new generation of cancer therapies, positioning itself at the forefront of personalized medicine.
The company’s stock performance over the past year has seen fluctuations, with a 52-week high of 4.84 EUR on October 15, 2025, and a low of 1.012 EUR on April 6, 2025. These variations reflect the inherent volatility in the biotechnology sector, influenced by clinical trial outcomes, regulatory developments, and market sentiment.
Cellectis SA’s strategic focus on gene editing and immunotherapy aligns with broader industry trends towards precision medicine. The company’s efforts in developing UCART therapies are particularly noteworthy, as they represent a significant advancement in the treatment of various cancers. By leveraging cutting-edge gene-editing technologies, Cellectis aims to enhance the efficacy and safety of CAR-T cell therapies, potentially offering new hope to patients with previously untreatable conditions.
The company’s dual listing on the NYSE and Euronext Paris stock exchanges provides it with a robust platform for raising capital and expanding its research and development initiatives. Since its Initial Public Offering (IPO) on February 7, 2007, Cellectis has demonstrated a commitment to innovation and growth, continually investing in its scientific capabilities and expanding its therapeutic pipeline.
Cellectis SA’s ongoing research and development efforts are supported by a strong foundation of scientific expertise and strategic partnerships. The company’s dedication to advancing cancer therapies through gene-edited T-cells positions it as a leader in the biotechnology sector, with the potential to significantly impact patient outcomes and the broader healthcare landscape.
As Cellectis SA continues to navigate the complexities of the biopharmaceutical industry, its focus on innovation and patient-centric therapies remains a driving force behind its strategic initiatives. The company’s commitment to developing next-generation cancer treatments underscores its role as a key player in the evolving field of immunotherapy, with the potential to transform the landscape of cancer care.
